# Xanomeline/trospium chloride PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/xanomeline-trospium

> The next catalyst for xanomeline/trospium chloride, sponsored by BRISTOL MYERS SQUIBB CO (BMY), is its topline data readout, Jun to Sep 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | xanomeline/trospium chloride |
| Codes | BMS-986510 |
| Sponsor | BRISTOL MYERS SQUIBB CO (BMY) https://sec-api.dev/companies/bmy/catalysts |
| Indications | [Schizophrenia](https://sec-api.dev/indications/schizophrenia), [Alzheimer's Disease](https://sec-api.dev/indications/alzheimer-s-disease), [Alzheimer Disease](https://sec-api.dev/indications/alzheimer-disease), Mania |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Jun to Sep 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Mania; Bipolar Disorder.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07140913 (A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-28 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07140913

### June 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Mania; Bipolar Disorder.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07140913 (A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-28 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07140913

### Nov 2028 to Feb 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Alzheimer Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07011732 (A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-24 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07011732

### Nov 2028 to Feb 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Alzheimer's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07011745 (A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-03 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07011745

### November 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Alzheimer's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07011745 (A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-03 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07011745

### November 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Alzheimer Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07011732 (A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-24 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07011732

### Mar to Jun 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Schizophrenia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07686263 (Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-03 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." https://clinicaltrials.gov/study/NCT07686263

### March 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Schizophrenia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07686263 (Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-03 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." https://clinicaltrials.gov/study/NCT07686263

## Same indication

- [[18f]pi-2620](https://sec-api.dev/pdufa/18f-pi-2620) (LNTH)
- [ALTO-101](https://sec-api.dev/pdufa/alto-101) (ANRO)
- [Anavex3-71 oral capsules](https://sec-api.dev/pdufa/anavex3-71-oral) (AVXL)
- [Brenipatide](https://sec-api.dev/pdufa/brenipatide) (LLY)
- [Cariprazine flexible dose](https://sec-api.dev/pdufa/cariprazine-flexible-dose) (ABBV)
- [Dn-tnf](https://sec-api.dev/pdufa/dn-tnf) (INMB)
- [Donanemab](https://sec-api.dev/pdufa/donanemab) (LLY)
- [Emraclidine](https://sec-api.dev/pdufa/emraclidine) (ABBV)
- [GSK4527226](https://sec-api.dev/pdufa/gsk4527226) (GSK)
- [GXV813](https://sec-api.dev/pdufa/gxv813) (NVS)
- [Igc-ad1-active](https://sec-api.dev/pdufa/igc-ad1-active) (IGC)
- [Fanapt® (iloperidone)](https://sec-api.dev/pdufa/iloperidone) (VNDA)
- [JNJ-63733657](https://sec-api.dev/pdufa/jnj-63733657) (JNJ)
- [JNJ-64042056](https://sec-api.dev/pdufa/jnj-64042056) (JNJ)
- [Karxt](https://sec-api.dev/pdufa/karxt) (BMY)
- [Lb-102 (50 mg tablet)](https://sec-api.dev/pdufa/lb-102) (LBRX)
- [Mevidalen](https://sec-api.dev/pdufa/mevidalen) (LLY)
- [MK-1167](https://sec-api.dev/pdufa/mk-1167) (MRK)
- [ML-007C-MA](https://sec-api.dev/pdufa/ml-007c-ma) (MPLT)
- [Ml-007c-ma bid](https://sec-api.dev/pdufa/ml-007c-ma-bid) (MPLT)
- [NBI-1117567](https://sec-api.dev/pdufa/nbi-1117567) (NBIX)
- [NBI-1117568](https://sec-api.dev/pdufa/nbi-1117568) (NBIX)
- [NBI-1117570](https://sec-api.dev/pdufa/nbi-1117570) (NBIX)
- [Olz/sam](https://sec-api.dev/pdufa/olz-sam) (ALKS)
- [Primec](https://sec-api.dev/pdufa/primec) (NRSN)
- [Remternetug](https://sec-api.dev/pdufa/remternetug) (LLY)
- [Sabirnetug](https://sec-api.dev/pdufa/sabirnetug) (ABOS)
- [BRIUMVI® (ublituximab)](https://sec-api.dev/pdufa/ublituximab) (TGTX)
- [VHB937](https://sec-api.dev/pdufa/vhb937) (NVS)
- [Xanomeline and trospium chloride capsules](https://sec-api.dev/pdufa/xanomeline-and-trospium) (BMY)

Calendar months: [June 2027](https://sec-api.dev/fda-calendar/2027-06), [November 2028](https://sec-api.dev/fda-calendar/2028-11)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/xanomeline-trospium.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Xanomeline/trospium chloride PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/xanomeline-trospium

```bibtex
@misc{secapidev_pdufa_xanomeline_trospium_20261116,
  title        = {Xanomeline/trospium chloride PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/xanomeline-trospium}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_xanomeline_trospium_20261116","title":"Xanomeline/trospium chloride PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/xanomeline-trospium","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
